Ascentage's Lisaftoclax Wins China Breakthrough Therapy Designation in First-Line CLL/SLL
AAPG is trading near its 52-week low of $14.455 (13% above the low) on light trading volume (0.2× avg).
Summary
Ascentage's lisaftoclax plus acalabrutinib received China's Breakthrough Therapy Designation for previously untreated CLL/SLL, a regulatory fast-track that could speed a front-line NDA but comes with no new data or dated milestone.
Key Events · Product Development and Regulatory · AAPG
-
China BTD for First-Line CLL/SLL
CDE of China's NMPA granted Breakthrough Therapy Designation to lisaftoclax (APG-2575) combined with acalabrutinib for treatment-naïve adult CLL/SLL.
-
What the Designation Unlocks
BTD gives priority CDE communications and development guidance, and allows application for Priority Review and conditional approval at NDA submission if conditions are met — no approval or revenue follows directly.
-
GLORA-2 Is the Real Test
The designation rests on a global registrational Phase III trial, GLORA-2, testing the combination as first-line CLL/SLL therapy; the filing gives no readout date.
-
Front-Line Expansion Beyond Current Label
Lisaftoclax was approved in China in July 2025 only for CLL/SLL patients already treated with a BTK inhibitor; first-line use would address a substantially larger patient population.
Analysis · AAPG · Life Sciences
China's CDE has granted Breakthrough Therapy Designation to lisaftoclax combined with acalabrutinib for treatment-naïve CLL/SLL — the larger, front-line market rather than the relapsed setting where lisaftoclax is already approved. No approval or revenue follows directly from the designation; its value is procedural, opening priority CDE dialogue and a potential path to Priority Review and conditional approval when an NDA is filed. The real test is the GLORA-2 global Phase III readout, which the filing does not date. For a company that posted a $120.4M H1 2026 net loss and is burning cash on R&D, a faster front-line path matters, but investors get no new efficacy data, no timeline, and no change to the $200M ATM overhang established in July.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 32.5% of the 1969 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AAPG was trading at $16.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $14.46 to $38.58. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.